依折麦布对进展性脑卒中患者的影响

摘要
图/表
参考文献(25)
相关文章 (11)

全文: PDF (598 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨依折麦布对进展性脑卒中患者的影响。方法选取2016年1月至2018年12月河北医科大学第二医院收治的423例进展性脑卒中患者为研究对象，依据随机数字表法将其分为对照组（214例）和依折麦布组（209例）。对照组采用基础治疗，依折麦布组在对照组的基础上给予依折麦布治疗，疗程14 d。比较两组治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、颈动脉斑块体积、白细胞介素6（IL-6）、金属基质蛋白酶9（MMP-9）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、三酰甘油（TG）及丙氨酸氨基转移酶（ALT）、总胆红素（TBil）水平；随访3个月比较两组的自理能力、居家情况及死亡情况。结果治疗前两组NIHSS评分比较，差异无统计学意义（P > 0.05）；治疗后依折麦布组NIHSS评分低于对照组，差异有高度统计学意义（P < 0.01）。随访3个月后两组患者的自理能力、居家情况及死亡率比较，差异无统计学意义（P > 0.05）。治疗前，两组患者颈动脉斑块体积、IL-6、MMP-9水平比较，差异无统计学意义（P > 0.05）。治疗后两组患者颈动脉斑块体积小于治疗前，且依折麦布组小于对照组，差异有统计学意义（P < 0.05）；两组IL-6、MMP-9水平低于治疗前，且依折麦布组低于对照组，差异有统计学意义（P < 0.05）。治疗前后两组TG、HDL-C水平比较，差异无统计学意义（P > 0.05）。治疗后依折麦布组TC、LDL-C水平低于治疗前，且依折麦布组低于对照组，差异有统计学意义（P < 0.05）。治疗前后两组ALT、TBil比较，差异无统计学意义（P > 0.05）。结论依折麦布可能是治疗进展性脑卒中的有效药物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨兰1 赵平平2 赵静1 王娟1 王晓鹏1

关键词 ：依折麦布, 进展性脑卒中, 颈动脉斑块, 白细胞介素6, 金属基质肽酶9

Abstract：Objective To explore the effect of Ezetimibe on patients with progressive stroke. Methods A total of 423 patients with progressive stroke admitted to the Second Hospital of Hebei Medical University from January 2016 to December 2018 were selected as the research objects. They were divided into control (214 cases) and Ezetimibe group (209 cases) by random number table method. Control group was received basic treatment, and Ezetimibe group was received Ezetimibe treatment on the basis of control group and the course of treatment was 14 days. National institutes of health stroke scale (NIHSS) score, carotid plaque volume, interleukin-6 (IL-6), metallomatrix proteinase 9 (MMP-9), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triacylglycerol (TG), alanine aminotransferase (ALT) and total bilirubin (TBil) were compared between two groups before and after treatment. The self-care ability, home condition and death of two groups were compared after three months follow-up. Results Before treatment, there were no significant differences in NIHSS scores between two groups (P > 0.05). NIHSS scores in Ezetimibe group were lower than those in control group after treatment, and the differences were highly statistically significant (P < 0.01). There were no significant differences in self-care ability, home condition, and death rate between two groups after three months follow-up (P > 0.05). Before treatment, there were no significant differences in carotid plaque volume, IL-6, and MMP-9 levels between two groups (P > 0.05). After treatment, carotid plaque volume in two groups were smaller than those before treatment, and Ezetimibe group was smaller than control group, and the differences were statistically significant (P < 0.05). IL-6 and MMP-9 levels in two groups were lower than those before treatment, and Ezetimibe group was lower than control group, and the differences were statistically significant (P < 0.05). There were no significant differences in TG and HDL-C levels between two groups before and after treatment (P > 0.05). After treatment, the levels of TC and LDL-C in Ezetimibe group were lower than those before treatment, and Ezetimibe group was lower than control group, and the differences were statistically significant (P < 0.05). There were no significant differencea in ALT and TBil between two groups before and after treatment (P > 0.05). Conclusion Ezetimibe may be an effective drug for the treatment of progressive stroke.

Key words： Ezetimibe Progressive stroke Carotid plaque Interleukin-6 Matrix metallopeptidase 9

基金资助:河北省医学科学研究重点课题计划项目（20160 567）。

作者简介: 杨兰（1981.7-），女，硕士，硕士生导师；研究方向：脑血管病诊疗及机制研究。

引用本文:

杨兰1 赵平平2 赵静1 王娟1 王晓鹏1. 依折麦布对进展性脑卒中患者的影响[J]. 中国医药导报, 2021, 18(20): 66-69,73.
YANG Lan1 ZHAO Pingping2 ZHAO Jing1 WANG Juan1 WANG Xiaopeng1. Effect of Ezetimibe on patients with progressive stroke. 中国医药导报, 2021, 18(20): 66-69,73.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I20/66

[1] Denes A，Thornton P，Rothwell NJ，et al. Inflammation and brain injury：acute cerebral ischaemia，peripheral and central inflammation [J]. Brain Behav Immun，2010，24（5）：708-723.
[2] Tsivgoulis G，Saqqur M，Sharma VK，et al. Timing of Recanalization and Functional Recovery in Acute Ischemic Stroke [J]. J Stroke，2020，22（1）：130-140.
[3] Yang L，Zhao P，Zhao J，et al. Effects of ezetimibe and anticoagulant combined therapy on progressing stroke：a randomized，placebo-controlled study [J]. J Neurol，2016，263（12）：2438-2445.
[4] Morillo-Hernandez C，Lee JJ，English JC，et al. Retrospective outcome analysis of 25 alopecia areata patients treated with simvastatin/ezetimibe [J]. J Am Acad Dermatol，2019，81（3）：854-857.
[5] Lin YC，Lai TS，Wu HY，et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease：A Systematic Review and Meta-Analysis [J]. Clin Pharmacol Ther，2020，108（4）：833-843.
[6] Colhoun HM，Leiter LA，Müller-Wieland D，et al. Effect of alirocumab on individuals with type 2 diabetes，high triglycerides，and low high-density lipoprotein cholesterol [J]. Cardiovasc Diabetol，2020，19（1）：14.
[7] Gencer B，Mach F，Murphy SA，et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction：A Prespecified Secondary Analysis From the FOURIER Trial [J]. JAMA Cardiol，2020，5（8）：1-6.
[8] Santos HO，Earnest CP，Tinsley GM，et al. Small dense low-density lipoprotein-cholesterol（sdLDL-C）：Analysis，effects on cardiovascular endpoints and dietary strategies [J]. Prog Cardiovasc Dis，2020，63（4）：503-509.
[9] 中华医学会神经病学分会，中华医学会神经病学分会，脑血管病学组，等.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，9（51）：666-682.
[10] Ouchi Y，Sasaki J，Arai H，et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older （EWTOPIA 75）：A Randomized，Controlled Trial [J]. Circulation，2019，140（12）：992-1003.
[11] Grundy SM，Stone NJ，Guideline Writing Committee for the 2018 Cholesterol Guidelines. 2018 Cholesterol Clinical Practice Guidelines：Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline [J]. Ann Intern Med，2019，170（11）：779-783.
[12] Allahyari A，Jernberg T，Hagstr?觟m E，et al. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction：a simulation study [J]. Eur Heart J，2020，41（40）：3900-3909.
[13] Qamar A，Giugliano RP，Bohula EA，et al. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial [J]. J Am Coll Cardiol，2019，74（8）：1057-1068.
[14] Oh M，Kim H，Shin EW，et al. Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation [J]. BMC Cardiovasc Disord，2019，19（1）：201.
[15] Li D，McCaw ZR，Wei LJ，et al. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older [J]. JAMA Cardiol，2020，19（1）：201.
[16] Amarenco P，Kim JS，Labreuche J，et al. Benefit of Targeting a LDL （Low-Density Lipoprotein） Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke [J]. Stroke，2020，51（4）：1231-1239.
[17] Jia C，Malone HM，Keasey MP，et al. Blood Vitronectin Induces Detrimental Brain Interleukin-6 and Correlates With Outcomes After Stroke Only in Female Mice [J]. Stroke，2020，51（5）：1587-1595.
[18] Ziegler L，Frumento P，Wallén H，et al. The predictive role of interleukin 6 trans-signalling in middle-aged men and women at low-intermediate risk of cardiovascular events [J]. Eur J Prev Cardiol，2020，27（2）：122-129.
[19] Huehnchen P，Muenzfeld H，Boehmerle W，et al. Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice [J]. Cell Death Dis，2020，11（1）：45.
[20] Gupta M，Blumenthal C，Chatterjee S，et al. Novel emerging therapies in atherosclerosis targeting lipid metabol-ism [J]. Expert Opin Investig Drugs，2020，29（6）：611-622.
[21] Saba L，Saam T，J?覿ger HR，et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications [J]. Lancet Neurol，2019，18（6）：559-572.
[22] Song P，Fang Z，Wang H，et al. Global and regional prevalence，burden，and risk factors for carotid atherosclerosis：a systematic review，meta-analysis，and modelling study [J]. Lancet Glob Health，2020，8（5）：e721-e729.
[23] Wen D，Du X，Nie SP，et al. Association between matrix metalloproteinase family gene polymorphisms and ischemic stroke：a meta-analysis [J]. Mol Neurobiol，2014， 50（3）：979-985.
[24] Zhong C，Yang J，Xu T，et al. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke [J]. Neurology，2017，89（8）：805-812.
[25] Shimizu H，Tominaga T，Ogawa A，et al. Cilostazol for the prevention of acute progressing stroke：a multicenter，randomized controlled trial [J]. J Stroke Cerebrovasc Dis，2013，22（4）：449-456.